A5030480720- Schizophrenia research and treatment
- Eating Disorders and Behaviors
- Suicide and Self-Harm Studies
- Bipolar Disorder and Treatment
- Mental Health Treatment and Access
- Child and Adolescent Psychosocial and Emotional Development
- Tryptophan and brain disorders
- Obsessive-Compulsive Spectrum Disorders
- Treatment of Major Depression
- Personality Disorders and Psychopathology
- Homicide, Infanticide, and Child Abuse
- Psychopathy, Forensic Psychiatry, Sexual Offending
- COVID-19 and Mental Health
- Psychosomatic Disorders and Their Treatments
- Body Image and Dysmorphia Studies
- Substance Abuse Treatment and Outcomes
- Mental Health Research Topics
- Maternal Mental Health During Pregnancy and Postpartum
- Family Caregiving in Mental Illness
- Child Abuse and Trauma
- Mental Health and Psychiatry
- Educational and Social Studies
- Psychiatric care and mental health services
- Healthcare Decision-Making and Restraints
- Psychotherapy Techniques and Applications
University of Milano-Bicocca
2016-2025
Azienda Ospedaliera San Gerardo
2016-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2020-2025
NIHR Maudsley Dementia Biomedical Research Unit
2025
King's College London
2025
Azienda Socio Sanitaria Territoriale Lariana
2018-2024
Agostino Gemelli University Polyclinic
2024
ASST Melegnano e della Martesana
2018-2023
University of Victoria
2021
University of British Columbia
2021
The treatment gap for people with mental disorders exceeds 50% in all countries of the world, approaching astonishingly high rates 90% least resourced countries, even serious associated significant role impairments 1,2,3. A number recent initiatives have called action to scale up services based on evidence effective interventions and respect human rights 4,5. Evidence treatments has been synthesized forthcoming Mental Health Gap Action Programme (mhGAP) guidelines World Organization (WHO)...
<h3>Importance</h3> This article briefly reports the experience of mental health services and lessons learned during coronavirus disease 2019 (COVID-19) crisis. In particular, this report offers opportunities to build on gained in managing COVID-19 emergency Departments Mental Health Addiction (DMHAs) Lombardy, wealthiest Italian region, which has approximately 10 million inhabitants. <h3>Observations</h3> Italy a National System divided into 134 DMHAs, 27 are Lombardy. 4 weeks after...
Bipolar depression accounts for most of the disease duration in type I and II bipolar disorder (BD), with few treatment options, often poorly tolerated. Many individuals do not respond to first-line therapeutic resulting treatment-resistant (B-TRD). Esketamine, S-enantiomer ketamine, has recently been approved (TRD), but no data are available on its use B-TRD.To compare efficacy esketamine two samples unipolar TRD, providing preliminary indications effectiveness B-TRD. Secondary outcomes...
Abstract A question that arises from the literature on therapy is whether second‐level treatment effective for patients with recurrent binge eating who fail first‐level treatment. It has been shown subjects do not stop after an initial structured cognitive‐behavioural (CBT) programme benefit additional CBT (A‐CBT) sessions; however, it suggested these resistant would even more cue exposure (CET) targeting features associated poor response (e.g . urge to in a and anxiety experienced presence...
ABSTRACT Objectives. To assess admission rates to seven General Hospital Psychiatric Wards (GHPWs) located in the Lombardy Region 40 days after start of Coronavirus disease 2019 (COVID-19) epidemic, compared similar periods 2020 and 2019. Methods. Anonymized data from regional psychiatric care register have been obtained analyzed. The GHPWs for approximately 1.4 million inhabitants a total 119 beds. Results. In 40-day period (February 21–March 31, 2020) COVID-19 epidemic Italy, prior...
Background: Post-stroke depression (PSD) is a common and serious complication after stroke. In this systematic review meta-analysis, we evaluated the association between early PSD mortality, considering depressive symptoms occurring within first 3 months neurological event. Methods: This meta-analysis was conducted following Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines based on studies indexed till May 2018 PubMed Web of Science databases. The relative risk (RR)...
Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy high safety. It is also indicated acute short-term treatment psychiatric emergency due to major depressive disorder (MDD) symptoms in adults with MDD suicidal thoughts/behavior. We here provide preliminary insights on esketamine nasal spray (ESK-NS) effectiveness safety among patients substance use (SUD) within sample...